DK0808162T3 - Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt - Google Patents

Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt

Info

Publication number
DK0808162T3
DK0808162T3 DK96902984T DK96902984T DK0808162T3 DK 0808162 T3 DK0808162 T3 DK 0808162T3 DK 96902984 T DK96902984 T DK 96902984T DK 96902984 T DK96902984 T DK 96902984T DK 0808162 T3 DK0808162 T3 DK 0808162T3
Authority
DK
Denmark
Prior art keywords
heart failure
congestive heart
carbazole compounds
treat congestive
carvedilol
Prior art date
Application number
DK96902984T
Other languages
Danish (da)
English (en)
Inventor
Gisbert Sponer
Klaus Strein
Mary Ann Lukas-Laskey
Robert Ruffolo Jr
Neil Shusterman
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0808162(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Application granted granted Critical
Publication of DK0808162T3 publication Critical patent/DK0808162T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
DK96902984T 1995-02-08 1996-02-07 Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt DK0808162T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1995103995 DE19503995C2 (de) 1995-02-08 1995-02-08 Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en) 1995-02-08 1995-06-07 Method of treatment for decreasing mortality resulting from congestive heart failure
PCT/EP1996/000498 WO1996024348A2 (fr) 1995-02-08 1996-02-07 Utilisation de composes de carbazole pour le traitement de l'insuffisance cardiaque congestive

Publications (1)

Publication Number Publication Date
DK0808162T3 true DK0808162T3 (da) 1999-11-15

Family

ID=26012210

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96902984T DK0808162T3 (da) 1995-02-08 1996-02-07 Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt

Country Status (27)

Country Link
US (6) US5760069A (fr)
EP (1) EP0808162B1 (fr)
JP (1) JP3546058B2 (fr)
KR (1) KR100295940B1 (fr)
CN (1) CN1093760C (fr)
AT (1) ATE179891T1 (fr)
AU (1) AU702106C (fr)
BR (1) BR9607111A (fr)
CA (1) CA2212548C (fr)
CZ (1) CZ292002B6 (fr)
DE (1) DE69602424T2 (fr)
DK (1) DK0808162T3 (fr)
ES (1) ES2134588T3 (fr)
FI (1) FI973255A (fr)
GR (1) GR3030966T3 (fr)
HK (1) HK1014861A1 (fr)
HU (1) HUP9900773A3 (fr)
NO (1) NO314830B1 (fr)
NZ (1) NZ301692A (fr)
PL (1) PL321737A1 (fr)
RO (1) RO121629B1 (fr)
RU (1) RU2197242C2 (fr)
SI (1) SI0808162T1 (fr)
SK (1) SK106897A3 (fr)
UA (1) UA55382C2 (fr)
WO (1) WO1996024348A2 (fr)
ZA (1) ZA96994B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
CZ123099A3 (cs) * 1996-10-09 1999-11-17 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corporation Limited Partnership No. 1 Farmaceutický prostředek pro inhibici stresem-aktivovaných protein kinas
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
CN1285738A (zh) * 1997-11-12 2001-02-28 泊灵格曼海姆药品公司及史密斯克莱恩贝克曼公司 卡维地洛的新的口服剂型
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1212053A4 (fr) * 1999-09-08 2004-08-11 Nitromed Inc Methodes de traitement et de prevention de l'insuffisance cardiaque au moyen de composes d'hydralazine et de dinitrate d'isosorbide ou de mononitrate d'isosorbide
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1244455B1 (fr) * 1999-10-29 2009-07-22 Nitromed, Inc. Methodes de traitement de maladies vasculaires caracterisees par une insuffisance du monoxyde d'azote
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
WO2002000216A1 (fr) 2000-06-28 2002-01-03 Teva Pharmaceutical Industries Ltd. Carvedilol
EP1385509A4 (fr) * 2001-04-02 2004-06-30 Smithkline Beecham Corp Methode de traitement
WO2003028718A1 (fr) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Nouvelles formulations de carvedilol
CA2462275A1 (fr) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Nouvelle composition de carvedilol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) * 2001-11-08 2001-11-08 Sahltech Ab Treatment of congestive heart failure
US6710184B2 (en) 2002-01-15 2004-03-23 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
EP2266590A3 (fr) 2002-02-22 2011-04-20 Shire LLC Système d'administration de substances actives et méthodes de protection et d'administration de substances actives
EP1499310A4 (fr) * 2002-04-30 2005-12-07 Sb Pharmco Inc Monocitrate monohydrate de carvedilol
AU2003302218A1 (en) * 2002-05-16 2004-06-18 Genelabs Technologies, Inc Aryl and heteroaryl compounds as antibacterial and antifungal agents
JP2005533823A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド リン酸カルベジロール塩および／またはその溶媒和物、対応する組成物、および／または治療方法
WO2004002472A1 (fr) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Hydobromure de carvedilol
ATE257384T1 (de) * 2002-07-25 2004-01-15 Boehringer Ingelheim Pharma Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
EP1686986A4 (fr) * 2003-11-25 2009-05-27 Sb Pharmco Inc Sels de carvedilol, compositions correspondantes, procedes d'administration et/ou de traitement
EP1686967A4 (fr) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Base libre de carvedilol, ses sels, formes anhydres ou solvats, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et methodes de traitement ou d'administration
EP1778267A4 (fr) * 2004-07-16 2010-01-06 Nitromed Inc Compositions et methodes associees a l'insuffisance cardiaque
WO2006135757A1 (fr) * 2005-06-09 2006-12-21 Teva Pharmaceutical Industries Ltd. Formes cristallines du carvedilol et leurs procedes de preparation
US20080293724A1 (en) * 2006-02-17 2008-11-27 Nitromed, Inc. Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007144785A2 (fr) * 2006-03-26 2007-12-21 Uti Limited Partnership Inhibiteurs du récepteur de la ryanodine et procédés associés
AU2007254283A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
SI2288373T1 (sl) 2008-05-16 2015-12-31 Corthera, Inc. Relaksin za uporabo pri zdravljenju dispneje, povezane z akutnim srčnim popuščanjem
JP6196551B2 (ja) 2010-04-12 2017-09-13 スパーナス ファーマシューティカルズ インコーポレイテッド ビロキサジン塩を製造する方法及びその新規な多形
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
CA3027368A1 (fr) * 2016-06-13 2017-12-21 Ascendia Pharmaceuticals, Llc Administration a liberation prolongee par voie parenterale de systemes de dispersion de carvedilol
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Also Published As

Publication number Publication date
UA55382C2 (uk) 2003-04-15
CZ246397A3 (cs) 1998-11-11
NO973667D0 (no) 1997-08-08
WO1996024348A3 (fr) 1996-10-03
KR19980702085A (ko) 1998-07-15
KR100295940B1 (ko) 2001-08-07
CN1093760C (zh) 2002-11-06
US20010044455A1 (en) 2001-11-22
JP3546058B2 (ja) 2004-07-21
AU702106B2 (en) 1999-02-11
ZA96994B (en) 1997-10-27
US5760069A (en) 1998-06-02
EP0808162A2 (fr) 1997-11-26
CN1185106A (zh) 1998-06-17
HUP9900773A2 (hu) 1999-07-28
ES2134588T3 (es) 1999-10-01
CA2212548C (fr) 1999-08-24
AU4718196A (en) 1996-08-27
ATE179891T1 (de) 1999-05-15
GR3030966T3 (en) 1999-11-30
FI973255A0 (fi) 1997-08-07
PL321737A1 (en) 1997-12-22
EP0808162B1 (fr) 1999-05-12
RU2197242C2 (ru) 2003-01-27
RO121629B1 (ro) 2008-01-30
SI0808162T1 (en) 1999-10-31
NZ301692A (en) 2000-09-29
DE69602424D1 (de) 1999-06-17
FI973255A (fi) 1997-08-07
NO973667L (no) 1997-08-08
USRE40707E1 (en) 2009-05-05
CA2212548A1 (fr) 1996-08-15
DE69602424T2 (de) 1999-10-07
USRE40000E1 (en) 2008-01-08
NO314830B1 (no) 2003-06-02
MX9706042A (es) 1998-06-30
HUP9900773A3 (en) 2000-04-28
HK1014861A1 (en) 1999-10-08
SK106897A3 (en) 1999-03-12
US5902821A (en) 1999-05-11
US20030105138A1 (en) 2003-06-05
BR9607111A (pt) 1997-11-04
JPH10513463A (ja) 1998-12-22
CZ292002B6 (cs) 2003-07-16
AU702106C (en) 2005-02-17
WO1996024348A2 (fr) 1996-08-15

Similar Documents

Publication Publication Date Title
DK0808162T3 (da) Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt
NO20013727L (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
NO973231L (no) Nye forbindelser
AU2001272666A1 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
IS4923A (is) Meðferðaráform við inngjöf á H+,K+-ATPasa-blokkara
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
MX9602442A (es) Un tratamiento con fluoroquinolona a dosis unica elevada.
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE69227583D1 (de) Arylmorpholine, herstellung und verwendung
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE69218200T2 (de) Behandlung von leberkrebs
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
NO20024545L (no) Fremgangsmåte for behandling av kongestiv hjertefeil
UA19674A (uk) Композиція для обробки коhтактhих ліhз
DK0703781T3 (da) Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom
DE69528068T2 (de) Conagenine zur prävention und behandlung von diarrhöe
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
PT1305020E (pt) Utilizacao de fibratos para a preparacao de um medicamento util no tratamento da insuficiencia cardiaca congestiva
FR2416890A1 (fr) Derives de 1,5-benzothiazepines, leur preparation et leurs utilisations therapeutiques
ATE74505T1 (de) Schmerzpraeparat.
UA36762A (uk) Спосіб лікування хворих на обмежену склеродермію
OA09519A (fr) D-acide aspartique b-hydroxamate en tant que medicament
UA22022A (uk) Спосіб лікуваhhя хворих з високим ризиком розвитку поліоргаhhої hедостатhості
HUP9802142A2 (hu) Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására
RU98105539A (ru) Способ лечения псориаза